Genetically modified endogenous gene and application thereof

By inserting eukaryotic expression promoter into the 5'UTR region of the endogenous gene, CRISPR/Cas9 technology is used to achieve overexpression of endogenous genes, the problem of overexpression of large or multiple genes in the prior art is solved, and the problem of overexpression of large genes or multiple genes is improved. Efficiency and flexibility of gene editing.

CN118910070APending Publication Date: 2024-11-08SHENZHEN FIRST CONDOR BIOSCIENCE CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411001326.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing gene editing technologies are difficult to achieve overexpression of large or multiple genes in mammalian cells, especially due to the limitation of viral vector capacity and the limitation of exogenous gene template vector capacity of technologies such as CRISPR Cas9, which makes it difficult to achieve the expected results.

Method used

Overexpression of endogenous genes is achieved by inserting eukaryotic expression promoters in the 5'UTR region of the endogenous gene using CRISPR/Cas9 gene editing technology, including inserting constitutive and inducible promoters into the CD103 endogenous gene, such as CMV, EF1α, NFAT, etc., realize the overexpression of multiple endogenous genes.

Benefits of technology

The overexpression of endogenous large genes (protein amino acid number >1k) was successfully achieved, and the overexpression of multiple endogenous genes was achieved through one-step gene editing, solving the problem of viral vector capacity limitation and insufficient vector capacity of exogenous gene template vectors. Improves gene editing efficiency and flexibility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910070A_ABST
    Figure CN118910070A_ABST
Patent Text Reader

Abstract

The invention discloses a gene-modified endogenous gene, eukaryotic expression promoters are inserted into a 5 'UTR region of the endogenous gene, and the exogenous promoters solve the problem of low-expression-level endogenous large genes (the number of protein amino acids gt; 1k) is difficult to realize overexpression through a virus vector, namely, the endogenous large gene (the protein amino acid number gt; 1k), so that overexpression of a plurality of endogenous genes is realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of cell gene editing, and in particular to a gene-edited cell endogenous gene and application thereof. Background Art

[0002] Gene overexpression is an important molecular biology technique that can be applied to gene function research, drug target screening, cell signaling pathway analysis, clinical disease diagnosis and gene therapy, etc. Protein expression is the most commonly used type of gene overexpression, which mainly introduces exogenous genes or increases the expression level of endogenous genes to make cells or organisms produce excessive amounts of target proteins.

[0003] At present, the protein expression of mammalian cells is mainly achieved by cloning the coding sequence of the target gene (a sequence between the protein translation start codon and the translation terminator) into the corresponding plasmid or viral vector, and using the regulatory elements constructed on the vector backbone, including promoters, enhancers, terminators and polynucleotide signals, so that the gene can be transcribed and translated in large quantities under artificial control, thereby achieving overexpression of the target gene. The current mainstream viral vectors include adeno-associated viruses, adenoviruses, lentiviruses and retroviruses; in addition, gene overexpression can also be achieved by using gene editing technologies such as CI RSPR Cas9, which mainly achieves the expression of exogenous genes by inserting exogenous gene coding sequences or expression frames into specific gene sites.

[0004] Although viral vectors and gene editing technologies have shown certain effects, this strategy also has obvious limitations. First, the capacity of viral vectors such as lentivirus is limited. When it is necessary to insert a longer target gene or insert multiple genes at the same time, this limitation will be particularly prominent and it is difficult to achieve the expected effect. Secondly, gene knock-in technologies such as CI RSPR Cas9 require the provision of homologous repair exogenous gene templates, and the vectors of exogenous gene templates often use adeno-associated viruses, and the exogenous gene capacity of adeno-associated viruses does not exceed 5kb. These factors also limit the use of gene editing technologies such as CI RSPR Cas9 in gene overexpression. Summary of the invention

[0005] Based on the above problems, the invention provides a gene expression technology for modifying endogenous genes through gene editing to achieve overexpression of endogenous genes; on the one hand, this method can achieve overexpression of endogenous large genes (number of protein amino acids > 1k); on the other hand, it can achieve overexpression of multiple endogenous genes through one-step gene editing.

[0006] The technical solution of the present invention is as follows:

[0007] A genetically modified endogenous gene, wherein a eukaryotic expression promoter is inserted into the 5'UTR region of the endogenous gene.

[0008] In one embodiment, in the endogenous gene, the number of protein amino acids encoded by the endogenous gene is greater than 1K, such as the CD103 endogenous gene.

[0009] In one embodiment, in the endogenous gene, the 5'UTR region is located in the upstream 1000 bp region of the endogenous gene.

[0010] In one embodiment of the endogenous gene, in the endogenous gene, the eukaryotic expression promoter includes a constitutive promoter and an inducible promoter.

[0011] In one embodiment, in the endogenous gene, the constitutive promoter is one or more of CMV, EF1α, SV40 or PGK promoters.

[0012] In one embodiment, in the endogenous gene, the inducible promoter is one or more of NFAT, IL-2, AP-1 or NFκB promoter.

[0013] The present invention also provides nucleic acid molecules and / or expression cassettes, recombinant cells, recombinant vectors, biological preparations and biological materials containing the above-mentioned endogenous genes; and the expression cassettes, recombinant vectors, recombinant proteins, recombinant microorganisms, recombinant cell lines or biological preparations can be widely used in the preparation of drug components for preventing and treating tumors or cancers.

[0014] The present invention provides a genetically modified endogenous gene, which solves the problem that large endogenous genes (protein amino acid number>1k) with low expression levels in cells are difficult to overexpress through viral vectors by inserting an exogenous promoter into the 5'UTR region of the endogenous gene in the cell, that is, it achieves overexpression of large endogenous genes (protein amino acid number>1k), thereby achieving overexpression of multiple endogenous genes. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 Schematic diagram of the target gene structure containing the CMV and EF1α promoter exogenous gene repair template in Example 1; wherein the left and right sides are homology arm sequences of the CD103 gene, and the middle is the nucleotide sequence of the promoter CMV and EF1α;

[0016] Figure 2 This is a schematic diagram of the target gene structure of the exogenous gene repair template containing the NFAT exogenous gene promoter in Example 2; wherein the left and right sides are homology arm sequences of the CD103 gene, and the middle is the nucleotide sequence of the promoter NFAT;

[0017] Figure 3 This is a schematic diagram of the target gene structure containing the CAR225, CD103 and CAR225-CD103 expression cassettes in Example 3;

[0018] Figure 4 This is a schematic diagram of the target gene structure containing the CAR225-CD103, CAR225-CMV, and CAR225-NFAT homologous repair gene fragments in Example 3. DETAILED DESCRIPTION

[0019] The preferred embodiments of the present invention are further described in detail below in conjunction with the accompanying drawings.

[0020] The promoter modification of endogenous genes in the cells provided by the present invention is preferably a mammalian cell. This promoter modification, the modification site is located in the 5'UTR region of the endogenous gene (such as CD103) immediately upstream of the gene of the protein coding sequence, such as the 1000bp region upstream of the gene of the protein coding sequence. Promoter modification is to use gene editing technology, such as CRISPR / Cas9, to insert a eukaryotic expression promoter of a mammalian cell expression system in the 5'UTR region of the endogenous gene immediately upstream of the gene of the protein coding sequence.

[0021] The specific plan is as follows:

[0022] CRISPR Cas9 gene editing technology was used to create a double-stranded DNA incision at the 5'UTR site of the endogenous gene CD103 of immune cells to enable the insertion of the exogenous promoter gene into the double-stranded DNA incision of the endogenous gene.

[0023] In the present invention, immune cells include T cells, NK cells, NKT cells, macrophages, gamma-delta T cells, TI L cells, TCR-T cells or other tumor-killing cells; preferably T cells.

[0024] The endogenous gene of the immune cell is preferably an endogenous gene encoding a protein with an amino acid number of 1K or more, such as the CD103 endogenous gene.

[0025] The exogenous promoter inserted into the 5'UTR region of the above endogenous gene is a eukaryotic expression promoter, including a constitutive promoter and an inducible promoter; wherein the constitutive promoter is one or more of CMV, EF1α, SV40 or PGK promoters; and the inducible promoter is one or more of NFAT, IL-2, AP-1 or NFκB promoters.

[0026] When an exogenous promoter is inserted into an endogenous gene, it is preferred that the 5'UTR region of the insertion site is located 1000 bp upstream of the endogenous gene.

[0027] Based on the genetically modified endogenous genes, the present invention also provides nucleic acid molecules and / or expression cassettes, recombinant cells, recombinant vectors, biological preparations, and biological materials containing the above endogenous genes; wherein the biological materials and recombinant vectors include gene recombination expression vectors and chimeric antigen receptors. The expression cassette is also an expression frame. When constructing the expression frame of immune cell genes, the vector delivery method includes one or more of lentivirus, retrovirus, common plasmid, episome, nano-delivery system, electrotransduction, or transposon.

[0028] The above expression cassettes, recombinant vectors, recombinant proteins, recombinant microorganisms, recombinant cell lines or biological preparations, etc., can be widely used in the preparation of drug components for preventing and treating tumors or cancers. Wherein, the biological preparation is a pharmaceutically acceptable carrier, diluent or excipient. The administration of the biological preparation can be carried out in any convenient manner, including by spraying, injection, swallowing, infusion, implantation or transplantation. The biological preparation can be used in drugs for preventing and / or treating solid tumors.

[0029] The expression cassette, recombinant vector, recombinant protein, recombinant microorganism, recombinant cell line or biological agent provided by the present invention are used in the preparation of biological agents for preventing and / or treating cancer or tumors, such as the use of the biological agent in a pharmaceutically acceptable carrier, diluent or excipient; the tumor is selected from blood tumors, solid tumors or a combination thereof; the blood tumor is selected from acute myeloid leukemia (AML), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) or a combination thereof; the solid tumor is selected from gastric cancer, gastric cancer peritoneal metastasis, liver cancer, leukemia, kidney tumor, lung cancer, small intestine cancer, bone cancer, prostate cancer, colorectal cancer, breast cancer, colon cancer, cervical cancer, ovarian cancer, lymphoma, nasopharyngeal carcinoma, adrenal tumor, bladder tumor, non-small cell lung cancer (NSCLC), glioma, endometrial cancer or a combination thereof.

[0030] Taking immune T cells as an example, the technical solution of the present invention is further described in detail through specific embodiments.

[0031] Example 1

[0032] In this embodiment, CRISPR / Cas9 gene editing technology is used to design an sgRNA nucleotide sequence that can create a double-stranded DNA cut on the endogenous gene, design a homology arm nucleotide sequence, and a nucleotide sequence on the left and right ends of homologous recombination-mediated repair (HDR); wherein the exogenous gene promoters are CMV and EF1α.

[0033] 1.1. Design of sgRNA for endogenous gene CD103

[0034] According to the CD103 gene sequence, three sgRNA sequences of TRAC of the CD103 gene were designed in the 1000bp region upstream of the start codon of the protein coding sequence. One of them was selected at random when used; the three sgRNA sequences were as follows:

[0035] The nucleic acid sequence of sgRNA1 is shown in SEQ ID NO. 1: CCCATGTGTCGCACTCGCCTCGG;

[0036] The nucleic acid sequence of sgRNA2 is shown in SEQ ID NO. 2: ACTCAAATGGATGATACGAACGG;

[0037] The nucleic acid sequence of sgRNA3 is shown in SEQ ID NO.3: ACACGACTGCCAGCTGTCAACGG.

[0038] 1.2. Design of homology arm nucleotide sequences

[0039] According to the different sgRNA nucleotide sequences designed in step 1.1 above, the corresponding left and right homologous arm nucleotide sequences of homologous recombination were designed respectively, and their nucleotide sequences are as follows:

[0040] 1.2.1, the nucleotide sequences of the left and right homology arms corresponding to sgRNA1 are shown in SEQ ID NO.4 and SEQ ID NO.5 respectively;

[0041] The nucleotide sequence shown in SEQ ID NO.4:

[0042] ACATGGGCCGTGGCCCACTCAGCTTCCCCTCAGCCAGGAGGCCAGGAGGCGGGGACAGAAGCACACACACCAGCAAGGACCCACAGACCGGCACTTTCAACCAAACAGAGACACTCCGGCTCGTACACAACCAGCCGTGTGGCTTCCTCAGTTGTGGGCTGGACCCTAGGAGCTTAGGGGCCACTGTCAGCCCCACTCTACCACCCACACTTTGACCCACACTTTCATGGAATAGGGAGCTGAGGTTTGGCCAGGGCCACAGTTCTAGGTGTCCTCAGCAGATGCTGGAGGTGCAGGAGCAACGTGAATCCAGCCTGCCGTTCGTATCATCCATTTGAGTCGGTCCCCTGTCCTGCCTCAGAACCTACCACCAGACATCTCAGCCCAGCTTCCAGCCCAGGGTCCTCGGTGGTGGTTGCCTCAGCACTGAGAC;

[0043] The nucleotide sequence shown in SEQ ID NO.5:

[0044] CTGCTCTGTAACAGAAGGGAGCTCTGCCAGGCGGAGCCTCCACACTCAGAGAACAAACTACAGAGTCAAGGACCTGCCCCAAGTGGGTGCCATGGGGAGAGGGCCTCGGTGGCGGGGGGAGGCTGGCTGGAGGAGGAACAGAATGGCAGAGCCCTGGAGTCCAAAGGCCCTGGCTGACAGAACTGGCAACACGAAGCCTCAGCCGCCCTTCCCAACAAGCCTGGGGCCCTGACCCACCGAGCAAGACTCCTTTCCTGGAGGAGCTGCCACTCTCTAACCTCTGGCTCTAACTGAGCCCCATCAGAGACAGACAGTCAAGGCTGTAGTCTGCAGACACCTGGCTGGAGCTGAGGGCACAGCAGCCCCTCGAAGCAGCGGGTGAGAGGACTTACTGGCTATGCAGAGCAGAGTGTGGAAGAGCCACATCCTTGCTGGAGCAGAGGCGGCTGTGTGGGAGCCGAGGCGAGTGCGAC;

[0045] 1.2.2, the left and right homology arm sequences corresponding to sgRNA2 are shown in SEQ ID NO.6 and SEQ ID NO.7 respectively;

[0046] The nucleotide sequence shown in SEQ ID NO.6:

[0047] TATCATCCATTTGAGTCGGTCCCCTGTCCTGCCTCAGAACCTACCACCAGACATCTCAGCCCAGCTTCCAGCCCAGGGTCCTCGGTGGTGGTTGCCTCAGCACTGAGACAGGCGTCCCCCTCCCATAGGAAGTGCCTCCCCAGCCAAAAACTGGGCTCTTGTACCAGCCCATGCACTCAAGGCCCTGGGGTTCTGGAGGGCCAGGTGAGTGGAAAGA CCCAACGCACTGAGTGAAATCACTGCCTCGATTCAACTTCGGCTGCGTTCATTCTCTTTAAAACCAGGACAGCAACCTGACGTGGAAACTGACTGAACAGGACTCTGAGTTACCAGAATAACAGAAGTAAAATTCTATACATCTTCCAGCATACCTGTGATGCATCCCAGCATTCCACAGAACACGCCGTTGACAGCTGGCAGTCGTGTTTAAGTG;

[0048] The nucleotide sequence shown in SEQ ID NO.7:

[0049] GCGGGTGAGAGGACTTACTGGCTATGCAGAGCAGAGTGTGGAAGAGCCACATCCTTGCTGGAGCAGAGGCGGCTGTGTGGGAGCCGAGGCGAGTGCGACACATGGGCCGTGGCCCACTCAGCTTCCCCTCAGCCAGGAGGCCAGGAGGCGGGGACAGAAGCACACACACCAGCAAGGACCCACAGACCGGCACTTTCAACCAAACAGAGACACTCCGGCTCGTACACAACCAGCCGTGTGGCTTCCTCAGTTGTGGGCTGGACCCTAGGAGCTTAGGGGCCACTGTCAGCCCCACTCTACCACCCACACTTTGACCCACACTTTCATGGAATAGGGAGCTGAGGTTTGGCCAGGGCCACAGTTCTAGGTGTCCTCAGCAGATGCTGGAGGTGCAGGAGCAACGTGAATCCAGCCTGCCGTTCG;

[0050] 1.2.3. The left and right homologous arm sequences corresponding to sgRNA3 are shown in SEQ ID NO.8 and SEQ ID NO.9 respectively;

[0051] The nucleotide sequence shown in SEQ ID NO.8:

[0052] CAGCTGGCAGTCGTGTTTAAGTGCTGATCTGAGATCTGTACTGTGTGACCAAGTCTGTGACACAGAAGGAACTCTCCTGCACCCCTGCTCCCCAGGCTGCTGGAAGTGCAGAGTGGCGCCGTCAAACAGAACTCTGCGCGGGGATGGAACTGCTCTAGGTCGACGCTGTCCAGGATGGTACTCATGAGCCACATATGGTACTAAACCCTTAAAATGCCACTAGAACAACTGATGAACTGAATTTTGTATATTTTATTTAATTTTAATTAAACGTAAAAAGGCAGGACATTCCAAGGCTCTCTAACACGAGTGTCTGCAGCCCCATTCGCTTTGAGATGTGAATGTGTTAACCCAGGGTGGACAATGGTGTTGACTTCATTACTAGATAAAAATCCATGTTATTTTGTTTCTCGCATTGAAAGGCTGCTTGGCTAAGG;

[0053] The nucleotide sequence shown in SEQ ID NO.9:

[0054] GCAACGTGAATCCAGCCTGCCGTTCGTATCATCCATTTGAGTCGGTCCCCTGTCCTGCCTCAGAACCTACCACCAGACATCTCAGCCCAGCTTCCAGCCCAGGGTCCTCGGTGGTGGTTGCCTCAGCACTGAGACAGGCGTCCCCCTCCCATAGGAAGTGCCTCCCCAGCCAAAAACTGGGCTCTTGTACCAGCCCATGCACTCAAGGCCCTGGGGTTCTGGAGGGCCAGGTGAGTGGAAAGACCCAACGCACTGAGTGAAATCACTGCCTCGATTCAACTTCGGCTGCGTTCATTCTCTTTAAAACCAGGACAGCAACCTGACGTGGAAACTGACTGAACAGGACTCTGAGTTACCAGAATAACAGAAGTAAAATTCTATACATCTTCCAGCATACCTGTGATGCATCCCAGCATTCCACAGAACACGCCGTTGA。

[0055] 1.3. Design of HDR template nucleotide sequence containing exogenous gene

[0056] Using the gene knock-in principle of CRISPR / Cas9, exogenous gene fragments such as EF1α and CMV promoter were inserted into the 5'UTR region of the endogenous gene CD103 gene to transform the promoter of the CD103 gene, thereby upregulating the gene expression of CD103; among them:

[0057] 1.3.1. The HDR nucleic acid sequence designed for the EF1α promoter is shown in SEQ ID NO.10:

[0058] GGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGATCCGGTGCCTAGAGAAG GTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAA GTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAG;

[0059] 1.3.2. The HDR nucleic acid sequence designed for the CMV promoter is shown in SEQ ID NO.11:

[0060] .

[0061] The target gene structure of the homologous recombination repair template designed for the exogenous gene CMV and EF1α promoter is as follows Figure 1 As shown, both ends are homology arm nucleotide sequences, and in the middle are the nucleotide sequences of promoters CMV and EF1α; wherein, target gene 1 and target gene 2 correspond to CMV and EF1α promoters, respectively; the lengths of target gene 1 and target gene 2 are 1.4 bp and 1.1 bp, respectively.

[0062] 1.4. Virus packaging

[0063] After designing the homologous recombination repair template of the exogenous gene, it is necessary to construct the homologous recombination repair template carrying the exogenous gene on the viral vector. The construction process is as follows:

[0064] First, the HDR template carrying the exogenous gene designed in step 1.3 was inserted into the AAV plasmid using M lu I and Not I restriction endonucleases;

[0065] Secondly, through the three-plasmid system (transfer plasmid rAAV, auxiliary plasmid Rep-Cap and helper virus plasmid Ad He lper), the recombinant AAV (rAAV) virus particles were obtained by transiently transfecting 293T cells with plasmids, and then the HDR templates carrying the exogenous genes CMV and EF1α were packaged on two AAV viruses respectively; the titer of each packaged rAAV virus particle was 1.0×10 13 GC / ml.

[0066] 1.5 T cell isolation and activation

[0067] Mononuclear cells were isolated from the donor's peripheral blood, and density gradient centrifugation was performed using ficol separation technology. T cells were enriched using a T cell sorting kit (CD3 Micro magnetic beads, human lyoph ilized, 130-097-043). Anti-CD3 / anti-CD28-coupled magnetic beads were used to activate, culture and expand T cells, CD3 / CD28 magnetic beads: T cells = 3:1; the culture medium used was X-VIVO culture medium containing a final concentration of 5% AB serum and a final concentration of 300 IU / ml rhIL-2. The sorted T cells were cultured in a constant temperature incubator at 37°C and 5% CO2 to obtain activated T cells for later use.

[0068] 1.6. Construction of T-EF1α cells and T-CMV cells

[0069] 1.6.1. Making double-stranded DNA cuts on T cells

[0070] Prepare 6 groups of T cells, centrifuge each group at 500g for 5 min, remove the supernatant and wash the T cell pellet twice with DPBS; 6 The volume of each group of T cells was 10 cells / 20 μl, and Lonza electrotransfer buffer (as shown in Table 1) was added to resuspend the T cell pellet; wherein the ratio of the components of Lonza electrotransfer buffer was Supplement 1:SE cell line solution=1:4.5.

[0071] Table 1 Lonza electroporation buffer composition

[0072]

[0073] According to 6ZU T cells, 6 groups of Cas9 RNP components were configured according to Table 2 (2 groups were prepared for the corresponding groups ①, ② and ③ in Table 2) and incubated at room temperature for 15 minutes to obtain 6 groups of Cas9-RNP complex solutions; after the incubation, the 6 groups of T cells resuspended in Lonza electroporation buffer were added to the 6 groups of Cas9-RNP complex solutions, and gently mixed to obtain 6 groups of T cell fluids; the 6 groups of T cell fluids were transferred to the bottom of the electroporation wells in the 16-well NucleocuvetteTM electroporation strip, and the 4D-NucleofectorTM electroporator was started, the Human T cells step electroporation program was used, and the electroporation operation was performed.

[0074] Table 2 Cas9 RNP component system

[0075] Reagents Mother liquor concentration Volume (μL) PGA 100mg / ml 0.8 sgRNA1, sgRNA2, or sgRNA3 100pmol / uL 0.5 TrueCut Cas9 5ug / uL 1.6 total 2.9

[0076] In Table 2, sgRNA1, sgRNA2 or sgRNA3 represent three groups of independent reagent components, that is, Table 2 contains three groups of Cas9-RNP component systems, namely: Group ①, sgRNA1, PGA and TrueCut Cas9; Group ②, sgRNA2, PGA and TrueCut Cas9; Group ③, sgRNA3, PGA and TrueCut Cas9; and sgRNA1, sgRNA2 or sgRNA3 are the three sgRNA nucleotide sequences designed and obtained in step 1.1 of this implementation.

[0077] After electroporation, 80 μl of preheated DPBS was immediately added to each electroporation well corresponding to each group of T cells, and the plates were moved to a 37°C incubator for incubation for 15 min. After incubation, a double-stranded DNA cut was made at the 5'UTR region 1000 bp upstream of the CD103 gene in each group of T cells.

[0078] 1.6.2. EF1α and CMV promoter insertion

[0079] 1 ml of X-VIVO complete medium, 20 μl of AAV virus (taken from the AAV virus containing the exogenous gene EF1α repair template constructed in step 1.4 of this example) and 10 μl of 1 mM AZD7648 inhibitor were mixed to obtain the first type of culture medium system; 3 groups of the first type of culture medium system were prepared for use;

[0080] Accordingly, 1 ml of X-VIVO complete medium, 20 μl of AAV virus (taken from the AAV virus containing the exogenous gene CMV repair template constructed in step 1.4 of this example) and 10 μl of 1 mM AZD7648 inhibitor were mixed to obtain the second major culture medium system; 3 groups of the second major culture medium system were prepared for use;

[0081] The 6 groups of T cells containing double-stranded DNA nicks obtained in step 1.6.1 are divided into two major categories (category 1 and category 2, as shown in Table 3), and each category corresponds to 3 groups of T cells, that is, category 1 and category 2 correspond to group ①, group ②, and group ③ of the Cas9-RNP component system in Table 2, respectively. The 6 groups of T cells containing double-stranded DNA nicks in category 1 and category 2 are transferred into the culture medium systems of category 1 and category 2, respectively, to obtain 6 groups of T cell suspensions corresponding to each; the 6 groups of T cell suspensions are placed in a 37°C, 5% CO2 constant temperature incubator for 24 hours; after the culture, 3 groups of T-EF1α cells (e.g., T-EF1α (1)-(3)) and 3 groups of T-CMV cells (e.g., T-CMV (1)-(3)) as shown in Table 3 are obtained.

[0082] 1.7. Detection of CD103 in T cells

[0083] The three groups of T-EF1α cells and three groups of T-CMV cells obtained in step 1.6.2 were cultured for 4 days respectively, and the expression of CD103+ in the six groups of T cells was detected using CD103 flow cytometry detection antibody (Cat. No. 350216, manufacturer BioLegend). The detection results are shown in Table 3.

[0084] Table 3. CD103 positive rate under different promoter transformation methods

[0085]

[0086] As shown in Table 3, when the promoters EF1α and CMV were inserted into the sgRNA1 site, the positive rates of CD103 were higher than those of the sgRNA2 and sgRNA3 sites. This may be because the sgRNA1 nucleotide sequence has a low off-target rate for T cells and is easier to create double-stranded DNA incisions, thereby improving the insertion efficiency of the exogenous promoter, which leads to a relatively high CD103 positive rate after the promoter-modified T cells.

[0087] Example 2

[0088] In this example, antigen-inducible CD103-T cells were prepared by inserting the exogenous gene NFAT promoter into the 5'UTR region of the CD103 gene of T cells.

[0089] 2.1. Design of sgRNA for CD103 gene

[0090] The nucleic acid sequence of sgRNA1 designed in step 1.1 of Example 1 is shown in SEQ ID NO.1.

[0091] 2.2. Design of homology arm nucleotide sequences

[0092] The left and right homology arm nucleotide sequences designed in step 2.1 of Example 1 are shown as SEQ ID NO.4 and SEQ ID NO.5 respectively.

[0093] 2.3. Design of homologous recombination repair HRD template carrying NFAT promoter

[0094] Using the gene knock-in principle of CRISPR / Cas9, the exogenous gene NFAT promoter gene fragment was inserted into the 5'UTR region of the endogenous gene CD103 gene to transform the CD103 gene promoter, thereby upregulating the gene expression of CD103; wherein:

[0095] The HRD template nucleic acid sequence designed for the NFAT promoter is shown in SEQ ID NO.12:

[0096] GGAGGAAAAACTGTTTCATACAGAAGGCGTGGAGGAAAAACTGTTTCATACAGAAGGCGTGGAGGAAAAACTGTTTCATACAGAAGGCGTGGAGGAAAAACTGTTTCATACAGAAGGCGTGGAGGAAAAACTGTTTCATACA GAAGGCGTGGAGGAAAAACTGTTTCATACAGAAGGCGTCCCGGGACATTTTGACACCCCCATAATATTTTTCCAGAATTAACAGTATAAATTGCATCTCTTGTTCAAGAGTTCCCTATCACTCTCTTTAATCACTACTCACA.

[0097] The target gene structure of the homologous recombination repair template designed for the exogenous gene NFAT promoter is as follows Figure 2 As shown, both ends are homology arm nucleotide sequences, and the middle is the nucleotide sequence of the NFAT promoter; the target gene containing the NFAT promoter is marked as target gene 3.

[0098] 2.4 Virus packaging

[0099] After designing the homologous recombination repair template of the exogenous gene NFAT, it is necessary to construct the homologous recombination repair template of the exogenous gene NFAT on the viral vector. The construction process is as follows:

[0100] First, the HDR template carrying the NFAT gene fragment designed in step 2.3 was inserted into the AAV plasmid using M lu I and Not I restriction endonucleases;

[0101] Secondly, through the three-plasmid system (transfer plasmid rAAV, auxiliary plasmid Rep-Cap and helper virus plasmid Ad He lper), the recombinant AAV (rAAV) virus particles were obtained by transiently transfecting 293T cells with plasmids, and then the HDR carrying the exogenous gene NFAT was packaged on the AAV virus; the titer of the packaged Raav virus particles was 1.0×10 13 GC / ml.

[0102] 2.5 T cell isolation and activation

[0103] The activated T cells prepared in step 1.5 of Example 1 were used.

[0104] 2.6. Construction of T-NFAT cells

[0105] 2.6.1. Double-stranded DNA cuts on T cells

[0106] Take one group of T cells, centrifuge at 500 g for 5 min, remove the supernatant and wash the T cell pellet twice with DPBS; 6 The volume of each cell was adjusted to 10 cells / 20 μl, and Lonza electroporation buffer (as shown in Table 1 of Example 1) was added to resuspend the T cell pellet.

[0107] Prepare 1 set of Cas9 RNP components according to Table 4 and incubate at room temperature for 15 minutes to obtain a Cas9-RNP complex solution. After the incubation, add the T cells resuspended in Lonza electroporation buffer to the Cas9-RNP complex solution, gently mix to obtain T cell solution, transfer the T cell solution to the bottom of the electroporation wells in the 16-well NucleocuvetteTM electroporation plate, start the 4D-NucleofectorTM electroporator, use the Human T cells step electroporation program, do not generate bubbles, and perform the electroporation operation.

[0108] Table 4 Cas9-RNP component system

[0109] Reagents Mother liquor concentration Volume (μL) PGA 100mg / ml 0.8 sgRNA1 100pmol / uL 0.5 TrueCut Cas9 5ug / uL 1.6 total 2.9

[0110] After the electrotransfer is completed, 80 μl of preheated DPBS is immediately added to the electrotransfer well, and the electrotransfer plate is moved to a 37°C incubator for incubation for 15 minutes. After the incubation, a double-stranded DNA cut is made at the 5'UTR region site 1000 bp upstream of the CD103 gene of the T cell.

[0111] 2.6.2. NFAT promoter insertion

[0112] Mix 1 ml of X-VIVO complete medium, 20 μl of AAV virus (taken from the AAV virus containing the exogenous gene NFAT repair template constructed in step 2.4 of this example) and 10 μl of 1 mM AZD7648 inhibitor to obtain a culture medium system; transfer the T cells containing double-stranded DNA nicks prepared in step 2.6.1 into the above-mentioned culture medium system to obtain a T cell suspension; place the T cell suspension in a constant temperature incubator at 37°C and 5% CO2 for 24 hours; after the culture is completed, T-NFAT cells are obtained.

[0113] 2.7 Detection of CD103 in T cells

[0114] After culturing the T-NFAT cells obtained in step 2.6 for 4 days, the cells were plated at 1.0 × 10 6 cells / well, T-NFAT cells were seeded into a 12-well plate, and CD3 / CD28 magnetic beads were added to each well at a ratio of CD3 / CD28 magnetic beads: T-NFAT cells = 3:1, and mixed with T-NFAT cells for activation for 24 hours, and then the activated T-NFAT cells were collected, and the expression of CD103+ in T-NFAT cells was detected using CD103 flow cytometry antibody (Cat. No. 350216, manufacturer BioLegend), and the flow cytometry results are shown in Table 5.

[0115] At the same time, after culturing the T cells (control group) obtained in step 1.5 of Example 1 for 4 days, the cells were incubated at 1.0×10 6 T cells were seeded into a 12-well plate at a ratio of CD3 / CD28 magnetic beads: T cells = 3:1. CD3 / CD28 magnetic beads were added to each well and mixed with T cells for activation for 24 hours. The activated T cells were then collected and CD103 flow cytometry detection antibody (Cat. No. 350216, manufacturer BioLegend) was used to detect the expression of CD103+ in T cells. The test results are shown in Table 5.

[0116] Table 5 Antigen-induced CD103 protein expression levels in T-NFAT cells

[0117]

[0118] As shown in Table 5, compared with the control group T cells, the proportion of T cells (T-NFAT cells) with the NFAT promoter inserted increased significantly, with an increase of more than 37 times. This shows that the NFAT promoter was successfully activated and started the expression of the CD103 gene in T cells, achieving the overexpression of the CD103 gene in T cells by the NFAT promoter.

[0119] Example 3

[0120] In this example, CAR-CD103 T cells were constructed by lentiviral method and CRISPR Cas9 gene editing method, respectively.

[0121] 3.1. Design of sgRNA for TRAC gene

[0122] For the exogenous gene CAR225, the nucleic acid sequence of the sgRNA was designed as shown in SEQ ID NO.13: AGAGTCTCTCAGCTGGTACA.

[0123] 3.2. Design of nucleotide sequences of homology arms carrying CAR225

[0124] According to the sgRNA in step 3.1, the corresponding left and right homologous arm nucleotide sequences are designed as shown in SEQ ID NO.14 and SEQ ID NO.15, respectively.

[0125] As shown in SEQ ID NO.14 nucleotide sequence:

[0126] CCTTTTTCCCATGCCTGCCTTTACTCTGCCAGAGTTATATTGCTGGGGTTTTGAAGAAGATCCTATTAAATAAAAGAATAAGCAGTATTATTAAGTAGCCCTGCATTTCAGGTTTCCTTGAGTGGCAGGCCAGGCCTGGCCGTGAACGTTCACTGAAATCATGGCCTCTTGGCCAAGATTGATAGCTTGTGCCTGTCCCTGAGT CCCAGTCCATCACGAGCAGCTGGTTTCTAAGATGCTATTTCCCGTATAAAGCATGAGACCGTGACTTGCCAGCCCCAGAGCCCCGCCCTTGTCCATCACTGGCATCTGGACTCCAGCCTGGGTTGGGGCAAAGAGGGAAATGAGATCATGTCCTAACCCTGATCCTCTTGTCCCACAGATATCCAGAACCCTGACCCTGCC;

[0127] As shown in SEQ ID NO.15 nucleotide sequence:

[0128] ACCAGCTGAGAGACTCTAAATCCAGTGACAAGTCTGTCTGCCTATTCACCGATTTTGATTCTCAAACAAATGTGTCACAAAGTAAGGATTCTGATGTGTATATCACAGACAAAACTGTGCTAGACATGAGGTCTATGGACTTCAAGAGCAACAGTGCTGTGGCCTGGAGCAACAAATCTGACTTTGCATGTGCAAACGCCT TCAACAACAGCATTATTCCAGAAGACACCTTCTTCCCCAGCCCAGGTAAGGGCAGCTTTGGTGCCTTCGCAGGCTGTTTCCTTGCTTCAGGAATGGCCAGGTTCTGCCCAGAGCTCTGGTCAATGATGTCTAAAACTCCTCTGATTGGTGGTCTCGGCCTTATCCATTGCCACCAAAACCCTCTTTTTACTAAGAAACAGT.

[0129] 3.3 Design of HRD template carrying CAR225

[0130] Using the gene knock-in principle of CRISPR / Cas9, the exogenous CAR225 gene fragment was inserted into the 5'UTR region of the endogenous CD103 gene to modify the gene expression of CD103. That is, the CAR225 nucleotide expression sequence was inserted into the exon 1 site of the T cell TRAC gene, and the TRAC gene promoter was used to drive the expression of the CAR225 gene.

[0131] Wherein, the nucleotide sequence of the CAR225 gene is shown in SEQ ID NO.16:

[0132]

[0133] For the CAR225 gene, the designed HDR template nucleotide sequence is shown in SEQ ID NO.17:

[0134]

[0135] 3.4 Virus Packaging

[0136] Figure 3 It is a schematic diagram of the target gene structure containing the CAR225, CD103 and CAR225-CD103 expression cassettes; among them, target gene 4, target gene 5 and target gene 6 correspond to the CAR225, CAR225-CD103 and CD103 expression cassettes, respectively; the lengths of target gene 4, target gene 5 and target gene 6 are 5.9bp, 2.3bp and 4.7bp, respectively.

[0137] according to Figure 3 As shown, the nucleotide sequence structures of the expression frames of CAR225, CAR225-CD103 and CD103 were synthesized, and the lentiviruses were packaged in 293T cells using a four-plasmid system, respectively, and named LV-CAR225, LV-CAR225-CD103, and LV-CD103. Since the lentivirus packaging process is a conventional process, it will not be repeated here.

[0138] Figure 4 It is a schematic diagram of the target gene structure containing CAR225-CD103, CAR225-CMV, and CAR225-NFAT homologous repair gene fragments; among them, target gene 7, target gene 8, and target gene 9 correspond to CAR225-CD103, CAR225-CMV, and CAR225-NFAT homologous repair gene fragments, respectively; the lengths of target genes 7-9 are 6.7bp, 3.7bp, and 3.4bp, respectively.

[0139] according to Figure 4 As shown, CAR225-CD103, CAR225-CMV, and CAR225-NFAT homologous repair gene fragments were synthesized, and adeno-associated viruses were packaged in 293T cells using a three-plasmid packaging system, named AAV-CAR225-CD103, AAV-CAR225-CMV, and AAV-CAR225-NFAT.

[0140] After 293T cells were infected with the virus for 48 h, the biological titer of the virus was detected by flow cytometry. The titers of lentivirus (LV) and adeno-associated virus (AAV) are shown in Table 6.

[0141] Table 6 Virus biological titer test results

[0142]

[0143] From Table 6, Figure 3 and 4It can be seen that the AAV-CAR225-CD103 virus could not be packaged because the length of the CAR225-CD103 gene was ≈6.7 kb, which far exceeded the vector capacity of the adeno-associated virus. The titer of the LV-CAR225 lentivirus was 1.44×10 8 UT / ml, LV-CAR225-CD103 lentivirus titer 5.91×10 5 TU / ml, the LV-CD103 lentivirus titer was 8.17×10 7 TU / ml, the titer of AAV-CAR225-CMV adeno-associated virus was 8.16×10 12 GC / ml, the virus titer of AAV-CAR225-NFAT was 7.69E×10 12 GC / ml, the virus titer of AAV-CMV was 6.12E×10 12 GC / ml, the virus titer of AAV-NFAT was 7.45E×10 12 The titer test results of AAV-CAR225-CD103 and LV-CAR225-CD103 showed that when the target gene length exceeded 5000kb or exceeded the capacity of the viral vector, the success rate of virus packaging was significantly reduced, and even the virus could not be packaged.

[0144] 3.5. CAR-T cell preparation

[0145] As shown in Table 7, relevant CAR-T cells are prepared according to the virus combination method; among them, a single lentivirus LV-CAR225-CD103 or two lentiviruses LV-CAR225 and LV-CD103 can be used to simultaneously infect T cells to prepare CAR225-CD103 T cells.

[0146] Table 7 CAR-T cells prepared by different virus combinations and their positive rates

[0147]

[0148] 3.5.1. Construction of CAR225-CD103 cells by lentiviral method (Group 1 in Table 7)

[0149] Mononuclear cells were isolated from the peripheral blood of the donors and subjected to density gradient centrifugation using the ficol separation technique. T cells were enriched using a T cell sorting kit (CD3 Micro magnetic beads, human lyoph ilized, 130-097-043). Anti-CD3 / anti-CD28-coupled magnetic beads were used to activate, culture and expand T cells, with CD3 / CD28 magnetic beads: T cells = 3:1. The culture medium used was X-VIVO culture medium containing a final concentration of 5% AB serum and a final concentration of 300 IU / ml rhIL-2. All T cells were cultured in a constant temperature incubator at 37°C and 5% CO2 to obtain activated T cells for later use.

[0150] T cells were 3.0×10 6 Cells / well were inoculated in a 6-well cell culture plate with 1050 μl per well. According to the lentivirus MOI=3, lentivirus LV-CAR225-CD103, LV-CAR225 and LV-CD103 were added to each well of the culture plate respectively; 1 ml of X-VIVO complete medium was added 6 hours after lentivirus infection, followed by rehydration every other day, and cultured for 6 consecutive days. Among them, the LV-CAR225-CD103 virus titer was low, and the added virus volume was about 152 μl, resulting in slow T cell proliferation. On the 6th day of culture, the expression of CAR225 and CD103 was detected by flow cytometry. The test results are shown in Table 7.

[0151] In Table 7, in the CAR225-CD103 T cells prepared by the LV-CAR225-CD103 lentivirus, the CAR positive rate was 93.9%, the CD103 positive rate was 36.7%, and the proportion of CAR and CD103 double positive T was 34.5%; in the CAR225-CD103 T cells prepared by the two lentiviruses of LV-CAR225 and LV-CD103, the CAR positive rate was 95.6%, the CD103 positive rate was 88.7, and the proportion of CAR and CD103 double positive T was 84.8%. Although the proportion of CAR and CD103 double positive cells in the CAR225-CD103 T cells prepared by the two lentiviruses of LV-CAR225 and LV-CD103 was high, the VCN detection results of the lentiviral vector showed that the VCN in the constructed CAR225-CD103 T was >20, far exceeding the VCN requirements of clinical CAR-T cell drugs (VCN <10). This result shows that the dual virus method is not suitable for clinical application.

[0152] 3.5.2. Construction of CAR225-CMV T cells and CAR225-NFAT T cells by lentivirus and CRISPR / Cas9 gene editing (Groups 2 and 4 in Table 7)

[0153] Prepare the T cells obtained in step 1.5 of Example 1 at a rate of 2.0×10 6 Cells / well were inoculated in a 24-well plate with 700 μl per well; according to the lentivirus MOI=3, lentivirus LV-CAR225 was added for infection for 24 hours, and then centrifuged to replace new X-VIVO complete medium. On the third day of T cell culture, the magnetic beads were removed using a magnetic stand, the T cells were washed once with DPBS after centrifugation, and the supernatant was removed by centrifugation, and the cells were resuspended in 20 μl electroporation buffer (Supplement 1: SE cell solution = 1: 4.5). The Cas9 RNP component system was configured according to Table 4 in Example 2, and after sufficient mixing, it was incubated at room temperature for 15 minutes to obtain the Cas9RNP complex. Subsequently, the Cas9 RNP complex was added to the T cell suspension, and after gentle mixing, the T cell-Cas9RNP suspension was transferred to the bottom of the electroporation well in the 16-well NucleocuvetteTM electroporation strip, and the 4D-NucleofectorTM electroporator was started, and the Human T cell st im electroporation program was used.

[0154] After electroporation, 80 μl of preheated DPBS was immediately added to each electroporation well, and the electroporation plate was moved to a 37°C incubator for 15 min. After the incubation process, 1 ml of X-VIVO complete medium was added to the 24-well cell culture plate, and the cells were incubated at an MOI of 1.0 × 10 5 / cells, add AAV-CMV and AAV-NFAT according to the 2nd combination and the 4th group in the table, respectively, and add AZD7648 inhibitor (working concentration 30 μM) respectively, mix and incubate, and after the incubation is over, transfer all the cell suspensions in the electroporation plate to a 24-well plate, culture for 24 hours, replace with fresh X-VIVO complete medium, and continue to culture until the 4th day.

[0155] On the fourth day of cell culture, the expression of CAR and CD103 was detected by flow cytometry. Among them, CD3 / CD28 magnetic beads were added to the T cells with NFAT knocked in 24 hours in advance, and the expression of CD103 was detected by flow cytometry 24 hours after antigen activation.

[0156] The results of flow cytometry are shown in Table 7. In CAR225-CMV T cells, the virus LV-CAR225 and AAV-CMV were added in combination (Group 2), and the CAR positive rate was 94.6%, the CD103 positive rate was 65.6%, and the CAR and CD103 double positive rate was 63.1%; in CAR225-NFAT T cells, the virus LV-CAR225 and AAV-NFAT were added in combination (Group 4), and the CAR positive rate was 95.6%, the CD103 positive rate was 55.8%, and the CAR and CD103 double positive rate was 53.4%. The VCN detection results of the virus showed that the VCN of the lentivirus (LV-CAR225) of the constructed CAR225-CMV T cells and CAR225-NFAT T cells was less than 10, while the VCN requirement of clinical CAR-T cell drugs (VCN<10). This result shows that lentivirus and CRISPR / Cas9 gene editing methods are suitable for clinical applications.

[0157] 3.5.2. Construction of CAR225-CMV T cells and CAR225-NFAT T cells by CRISPR / Cas9 gene editing (Groups 3 and 5 in Table 7)

[0158] The T cells obtained in step 1.5 of Example 1 were used and 2.0×10 6 Cells / well were inoculated in a 24-well plate with 700 μl per well. After the third day of T cell culture, the magnetic beads were removed using a magnetic stand, and the T cells were washed once with DPBS after centrifugation, and the supernatant was removed by centrifugation. The cells were resuspended in 20 μl of electroporation buffer (Supplement 1: P3 pr imary cell solution = 1: 4.5). Cas9 RNP components were configured according to Table 8, mixed thoroughly, and incubated at room temperature for 15 minutes to obtain a Cas9-RNP complex solution.

[0159] Table 8 Double knockout Cas9 RNP components

[0160]

[0161] Subsequently, the Cas9-RNP complex solution was added to the T cell suspensions of groups 3 and 5, respectively, and gently mixed to obtain a mixture of T cells and Cas9 RNP. The mixture of T cells and Cas9 RNP was transferred to the bottom of the electroporation wells in the 16-well NucleocuvetteTM electroporation plate, and the 4D-Nuc leofectorTM electroporator was started, using the Human T cells step electroporation program.

[0162] After electroporation, 80 μl of preheated DPBS was immediately added to each electroporation well, and the electroporation plate was moved to a 37°C incubator for 15 min. After the incubation process, 1 ml of X-VIVO complete medium was added to the 24-well cell culture plate, and the cells were incubated at an MOI of 1.0 × 10 5 / cell, add 24.5μl virus AAV-CAR225-CMV and 26μl virus AAV-CAR225-NFAT, and add 10μl 1mM AZD7648 inhibitor, mix well and then electrotransfer. After the incubation is completed after electrotransfer, transfer all the cell suspension in the electrotransfer plate to a 24-well plate, culture for 24h, replace with fresh X-VIVO complete medium, and continue to culture until the 4th day.

[0163] After the fourth day of cell culture, the expression of CAR and CD103 was detected by flow cytometry. Among them, CD3 / CD28 magnetic beads were added to the T cells with NFAT knocked in 24 hours in advance, and the expression of CD103 was detected by flow cytometry 24 hours after antigen activation.

[0164] As shown in Table 7, the flow cytometry results showed that in the CAR225-CMV T double knockout cells (Group 3), the CAR positive rate was 62.6%, the CD103 positive rate was 59.2%, and the CAR and CD103 double positive rate was 45.3%; in the CAR225-NFAT T double knockout cells (Group 5), the CAR positive rate was 60.5%, the CD103 positive rate was 54.9%, and the CAR and CD103 double positive rate was 35.5%. These results show that the knock-in of exogenous genes at two gene loci can be achieved by one HDRT, and the overexpression of endogenous genes can be achieved by inserting exogenous promoters.

[0165] It can be seen from this embodiment that by using sgRNA and combining CRISPR / Cas9 technology, a CAR with TRAC site-specific integration can be constructed in one step, and T cells that highly express CD103 because the CD103 endogenous gene is modified. Compared with the traditional lentiviral method, this method can reduce the high cost caused by the use of lentiviruses in the preparation process of CAR-T, and effectively circumvent the capacity limitation of lentiviral vectors, greatly reducing the preparation cost of CAR-T; at the same time, the CAR element and the exogenous promoter are respectively inserted into the specific sites of the TRAC gene and the CD103 gene, thereby reducing the potential safety hazards caused by random insertion of viruses. Therefore, this embodiment proves that the 5'UTR region of the endogenous gene can achieve the regulation of overexpression of the endogenous gene after inserting the eukaryotic expression promoter.

[0166] It should be understood that the above description of the preferred embodiments of the present invention is relatively detailed and cannot be regarded as limiting the scope of patent protection of the present invention. The scope of patent protection of the present invention shall be based on the attached claims.

Claims

1. A genetically modified endogenous gene, characterized in that: A eukaryotic expression promoter is inserted into the 5'UTR region of the endogenous gene.

2. The endogenous gene according to claim 1, characterized in that The number of protein amino acids encoded by the endogenous gene is more than 1K.

3. The endogenous gene according to claim 1, characterized in that The 5'UTR region is located in the upstream 1000 bp region of the endogenous gene.

4. The endogenous gene according to claim 1, characterized in that The eukaryotic expression promoter includes a constitutive promoter and an inducible promoter.

5. The endogenous gene according to claim 4, characterized in that The constitutive promoter includes one or more of CMV, EF1α, SV40 and PGK promoters; the inducible promoter includes one or more of NFAT, IL-2, AP-1 and NFκB promoters.

6. A nucleic acid molecule, characterized in that The nucleic acid molecule comprises the endogenous gene according to any one of claims 1 to 5.

7. An expression cassette, characterized in that The expression cassette comprises the endogenous gene according to any one of claims 1 to 5, or comprises the nucleic acid molecule according to claim 6.

8. A recombinant cell line, characterized in that The recombinant cell line comprises the endogenous gene according to any one of claims 1 to 5, or comprises the nucleic acid molecule according to claim 6, or comprises the expression cassette according to claim 7.

9. A biological agent, characterized in that: The biological preparation comprises the endogenous gene described in any one of claims 1 to 5, or comprises the recombinant cell line described in claim 8.

10. A pharmaceutical composition for preparing a drug for treating tumors and cancers, characterized in that: The pharmaceutical composition comprises the recombinant cell line according to claim 8, or comprises the biological preparation according to claim 9.